PX1 Research provides certified, high-purity CJC-1295 without DAC (Modified GRF 1-29) optimized for rigorous in vitro and preclinical laboratory applications. Manufactured in the USA within GMP-compliant, ISO 17025-accredited facilities, every lot undergoes rigorous analytical testing to guarantee precise peptide sequence integrity and exceptional purity.
PX1 Research provides certified, high-purity CJC-1295 without DAC (Modified GRF 1-29) optimized for rigorous in vitro and preclinical laboratory applications. Manufactured in the USA within GMP-compliant, ISO 17025-accredited facilities, every lot undergoes rigorous analytical testing to guarantee precise peptide sequence integrity and exceptional purity.
When procuring CJC-1295 without DAC for sale, research institutions require absolute chemical purity, sequence fidelity, and verifiable lot-to-lot consistency. CJC-1295 without DAC—chemically designated as Modified GRF 1-29—is a 29-amino-acid synthetic peptide analog of endogenous Growth Hormone-Releasing Hormone (GHRH). Unlike its long-acting DAC-conjugated counterpart, CJC-1295 without DAC is synthesized specifically to preserve the natural physiological pulsatility of growth hormone secretion in controlled laboratory models.
PX1 Research supplies laboratory-grade CJC-1295 without DAC produced exclusively in the United States. Designed strictly for non-clinical research use, each batch undergoes independent third-party analysis, including Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS). Laboratories evaluating GHRH receptor kinetics, tissue repair signaling, or metabolic pathways can access detailed Certificates of Analysis (COAs) for every lot directly through our research portal.
Endogenous GHRH is a 44-amino-acid peptide, though its biological activity is fully retained within the N-terminal 1-29 fragment known as sermorelin. However, native GRF 1-29 is rapidly degraded in biological systems by enzymes such as dipeptidyl peptidase IV (DPP-IV). CJC-1295 without DAC incorporates four specific amino acid substitutions into the GRF 1-29 sequence to dramatically enhance enzymatic resistance while retaining selective binding affinity for the GHRH receptor.
The specific sequence modifications include D-Alanine at position 2, Glutamine at position 8, Alanine at position 15, and Leucine at position 27 (often abbreviated as Tetrasubstituted GRF 1-29). The substitution of D-Ala at position 2 protects the N-terminal cleavage site against DPP-IV enzymatic degradation. The additional substitutions stabilize the tertiary alpha-helical structure of the molecule, extending its biological half-life in vitro and in vivo from approximately 5-10 minutes to roughly 30 minutes without requiring covalent attachment to serum proteins.
CJC-1295 without DAC functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR), a Class B G-protein-coupled receptor primarily expressed on pituitary somatotropes. Upon receptor binding, the peptide stimulates the Gs-alpha subunit, triggering the activation of membrane-bound adenylyl cyclase. This activation leads to a transient influx of intracellular cyclic adenosine monophosphate (cAMP).
Elevated cAMP levels activate protein kinase A (PKA), which subsequently phosphorylates downstream transcription factors such as CREB (cAMP response element-binding protein). This intracellular cascade promotes the transcription of the growth hormone gene and stimulates the exocytosis of pre-stored somatotropic secretory vesicles. Preclinical investigations demonstrate that because CJC-1295 without DAC lacks the Drug Affinity Complex (DAC), it does not cause continuous, non-physiologic GHRHR activation. Instead, it allows the receptor to undergo natural desensitization and resensitization cycles, mimicking endogenous pulsatile secretion patterns. Researchers interested in broader receptor interactions can review our GHRH analogs mechanism overview.
A critical distinction in secretagogue research lies between CJC-1295 without DAC (Modified GRF 1-29) and CJC-1295 with DAC (Drug Affinity Complex). The DAC moiety consists of a maleimidopropionic acid reactive group conjugated to the C-terminus, enabling covalent binding to circulating serum albumin upon administration. This extends the biological half-life to over 6-8 days in animal models, resulting in continuous, elevated basal GH release.
In contrast, CJC-1295 without DAC possesses a half-life of approximately 30 minutes, producing discrete, controlled GH peaks without inducing baseline hypersecretion. For experimental designs aimed at studying physiological circadian GH dynamics, sleep-architecture modulation, or transient somatotrope stimulation, CJC-1295 without DAC is generally selected over long-acting variants. Researchers can evaluate our complete catalog of research peptides to select the optimal pharmacokinetic profile for their specific assay protocols.
Preclinical models consistently demonstrate that administration of CJC-1295 without DAC induces a pronounced, transient elevation in circulating growth hormone concentrations. Following somatotropic GH release, the hormone binds to hepatic growth hormone receptors, stimulating the transcription and secretion of Insulin-like Growth Factor 1 (IGF-1) and its primary binding protein, IGFBP-3.
In rodent models of tissue regeneration, sustained IGF-1 transcription promoted by GHRH analogs has been associated with accelerated satellite cell activation in skeletal muscle, enhanced collagen cross-linking in extracellular matrix studies, and modulated lipid metabolism. Because CJC-1295 without DAC preserves pulsatile dynamics, downstream feedback mechanisms via somatostatin remain functional, preventing total somatotropes exhaustion in extended animal studies.
In secretagogue research, GHRH analogs are frequently studied in combination with Growth Hormone Releasing Peptides (GHRPs) or ghrelin receptor agonists. While GHRH analogs stimulate adenylyl cyclase/cAMP pathways via GHRHR, ghrelin agonists signal through the Growth Hormone Secretagogue Receptor (GHS-R1a) via the phospholipase C (PLC) and intracellular calcium pathway.
Preclinical data show a synergistic amplification of GH release when CJC-1295 without DAC is evaluated alongside selective GHS-R agonists. For instance, co-administering Modified GRF 1-29 with Ipamorelin, GHRP-2, or early-generation analogs like Sermorelin yields a multi-fold increase in peak GH output compared to either agent tested in isolation. This dual-pathway stimulation model is widely utilized to examine maximum somatotropic reserve capacity in aging or damage-induced animal models. Learn more about these interactions in our detailed analysis of growth hormone secretagogues preclinical review.
Substandard peptide synthesis can introduce truncated sequences, deletion peptides, and residual organic reagents that invalidate experimental data. PX1 Research mandates stringent analytical verification for every production lot of CJC-1295 without DAC. Our quality control workflow utilizes high-resolution Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to verify chemical purity levels equal to or exceeding 99.0%.
Sequence identity is confirmed using Electrospray Ionization Mass Spectrometry (ESI-MS), verifying exact molecular mass against theoretical target values. Furthermore, because bacterial lipopolysaccharides can disrupt cell culture assays and provoke non-specific inflammatory responses in preclinical models, all PX1 peptides undergo Chromogenic Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain strictly below <0.01 EU/mg. Institutional accounts seeking bulk testing validation can coordinate directly via our wholesale portal.
CJC-1295 without DAC is supplied as a sterile, lyophilized cake inside borosilicate glass vials sealed under inert atmosphere. To ensure accurate assay concentrations and prevent peptide aggregation, proper reconstitution techniques must be adhered to within laboratory settings.
Reconstitution should be performed using sterile Bacteriostatic Water (containing 0.9% benzyl alcohol) or sterile isotonic saline, depending on assay sensitivity to preservative agents. The diluent should be introduced down the inner glass wall of the vial rather than sprayed directly onto the lyophilized powder. The vial should be gently swirled until complete dissolution is observed; vigorous mechanical vortexing must be avoided to prevent denaturation of the peptide's secondary alpha-helical structure.
Lyophilized CJC-1295 without DAC maintains chemical stability for up to 24 months when stored at -20°C in a desiccated environment protected from direct light exposure. For long-term archive storage, maintaining temperatures at -80°C minimizes chemical degradation mechanisms such as oxidation of methionine residues or deamidation of asparagine positions.
Once reconstituted into aqueous solution, the peptide is susceptible to hydrolysis and microbial growth over time. Reconstituted solutions should be stored at 2°C to 8°C and utilized within 14 to 28 days depending on the reconstitution medium used. Repeated freeze-thaw cycles must be strictly avoided; researchers are advised to prepare single-use aliquots using sterile microcentrifuge tubes immediately following initial reconstitution.
Procuring reliable reagents is critical for maintaining reproducible experimental conditions. PX1 Research is dedicated to supporting academic, biotechnology, and institutional laboratories across North America with chemical compounds manufactured under rigorous domestic oversight.
All orders are processed and fulfilled directly from our modern facilities located in California and Arizona, guaranteeing rapid same-day dispatch for orders finalized prior to cutoff times. Every order includes lot-matched COAs, mass spectra reports, and HPLC chromatograms. Academic labs and commercial entities requiring bulk quantities or customized synthesis parameters are encouraged to contact our institutional supply team.
What is the difference between CJC-1295 without DAC and Modified GRF 1-29?
CJC-1295 without DAC and Modified GRF 1-29 refer to the exact same chemical structure: a tetrasubstituted 29-amino-acid peptide analog of human GHRH lacking the C-terminal Drug Affinity Complex attachment.
What purity standard does PX1 Research guarantee for CJC-1295 without DAC?
PX1 Research guarantees a minimum purity of 99.0% for every batch of CJC-1295 without DAC, verified independently via RP-HPLC and ESI-MS mass spectrometry.
How is endotoxin content measured and limited in PX1 peptide products?
Every lot undergoes Chromogenic LAL testing to verify endotoxin levels are under <0.01 EU/mg, preventing cellular toxicity and immune interference in sensitive research assays.
Why is CJC-1295 without DAC preferred over CJC-1295 with DAC in certain studies?
CJC-1295 without DAC has a short half-life (~30 minutes), enabling researchers to study pulsatile, physiological spikes of growth hormone rather than the continuous basal elevation induced by the long-acting DAC version.
What diluent should be used to reconstitute CJC-1295 without DAC for laboratory use?
Reconstitution is typically performed using sterile Bacteriostatic Water (0.9% benzyl alcohol) for multi-use laboratory procedures or sterile 0.9% Sodium Chloride for specific in vitro assays requiring preservative-free media.
What is the recommended storage temperature for reconstituted CJC-1295 without DAC?
Reconstituted liquid solutions should be stored at 2°C to 8°C (refrigerated) and used within 14 to 28 days. Avoid repeating freeze-thaw cycles by aliquoting solutions into single-use vials.
Can CJC-1295 without DAC be evaluated alongside ghrelin receptor agonists?
Yes, in preclinical studies, GHRH analogs like CJC-1295 without DAC are frequently paired with GHS-R agonists (such as Ipamorelin) to evaluate synergistic GH release via dual distinct intracellular pathways.
Where are PX1 Research peptides manufactured and shipped from?
PX1 Research peptides are manufactured in US-based GMP-compliant laboratories and shipped directly from our primary distribution centers in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.